drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T-cell therapy)
drug_description
Autologous BCMA-directed CAR T-cell therapy in which a patient's T cells are engineered ex vivo to express a CAR recognizing BCMA on malignant plasma cells, triggering cytokine release and cytolytic killing in multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Idecabtagene Vicleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified ex vivo to express a chimeric antigen receptor targeting BCMA on malignant plasma cells; CAR engagement triggers T-cell activation, cytokine release, proliferation, and perforin/granzyme-mediated cytolytic killing of BCMA-positive cells in multiple myeloma.
drug_name
Idecabtagene vicleucel (ide-cel)
nct_id_drug_ref
NCT06357754